SCHEMBL7674292

SCHEMBL7674292

CCCc1ccc(C(=O)Nc2ccc(S(=O)(=O)NCC(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.54
ALDH1A1 P00352 4/20 0.53
LMNA P02545 3/20 0.53
PRMT1 Q99873 2/20 0.48
KDM4E B2RXH2 3/20 0.47
F2 P00734 1/20 0.46
TMPRSS6 Q8IU80 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
PPARA Q07869 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.44
GALR3 O60755 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7669959 0.93 KDM4E (0.53) ENPP1ALDH1A1LMNAPRMT1KDM4E
SCHEMBL7669245 0.92 KDM4E (0.52) ENPP1ALDH1A1LMNAPRMT1KDM4E
SCHEMBL7673461 0.92 KDM4E (0.52) ENPP1ALDH1A1LMNAPRMT1KDM4E
SCHEMBL7671606 0.92 KDM4E (0.52) ENPP1ALDH1A1LMNAPRMT1KDM4E
SCHEMBL7670801 0.91 LMNA (0.52) ALDH1A1LMNAPRMT1KDM4EF2
SCHEMBL5092484 0.87 MEN1 (0.55) ALDH1A1LMNAKDM4EF2TMPRSS6
SCHEMBL7667880 0.87 LMNA (0.54) ALDH1A1LMNAPRMT1KDM4EF2
SCHEMBL7670379 0.86 ALDH1A1 (0.50) ALDH1A1LMNAPRMT1KDM4EF2
SCHEMBL7667906 0.86 KMT2A (0.56) ALDH1A1LMNAF2TMPRSS6SMN1; SMN2
SCHEMBL7671859 0.86 PRMT1 (0.56) ENPP1ALDH1A1LMNAPRMT1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed